About Us Careers Contact Us

Inquiry List

* Name:
* Phone:
* Service & Products of Interested: [Isotope Labeled Inhibitors] Plinabulin-[13C6]
Project Description:
* Quantity
* Email:
* Organization We recommend you to leave us your work email address so that we can serve you better. Please leave your organization information here if you don't have a work email address.
* Verification Code:

Our Highlights

Optimal Prices
Buying products on this site guarantees the best price
Flexible Batches
Flexible batch size to meet different needs of global customers
Prompt Delivery
Warehouses in multiple cities to ensure timely delivery
Quality Assurance
Strict process parameter control to ensure product quality
One-to-one Customization
One-to-one custom synthesis for special structural needs

Application Area

Environmental

Stable isotope-labeled compounds are used as environmental pollutant standards for the detection of air, water, soil, sediment and food.

Clinical diagnostic

In addition to treating various diseases, isotopes are used for imaging, diagnosis, and newborn screening.

Organic Chemistry

Small molecule compounds labeled with stable isotopes can be used as chemical reference for chemical identification, qualitative, quantitative, detection, etc. Various types of NMR solvents can be used to study the structure, reaction mechanism and reaction kinetics of compounds.

Metabolic Research

Stable isotope labeling allows researchers to study metabolic pathways in vivo in a safe manner.

Plinabulin-[13C6]

Inquiry

General Information
Catalog: BLP-001388
Molecular Formula: C13[13C]6H20N4O2
Molecular Weight: 342.34

Chemical Structure

Description	Labelled Plinabulin. Plinabulin is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 value of 9.8~18 nM in tumor cells under the development of Nereus Pharmaceuticals. It can bind to the colchicine binding site of b-tubulin preventing polymerization and disrupting the cytoplasmic microtubule network. In Sep 2016, BeyondSpring Pharmaceuticals planed a phase II/III trial for Neutropenia. Phase I clinical trials for Solid tumours and Phase III clinical trials for Non-small cell lung cancer are on-going.
Synonyms	(3Z,6Z)-3-[[5-(1,1-dimethylethyl)-1H-imidazol-4-yl]methylene]-6-(phenylmethylene)-2,5-Piperazinedione-13C6
Related CAS	714272-27-2 (unlabelled)
Purity	98%; 99% atom 13C
Appearance	Yellow to white powder